{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Cancer cells", "Cancer stem cells", "Combination therapy", "Conventional cancer therapy", "Natural products", "Thymoquinone"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34367926", "DateRevised": {"Year": "2021", "Month": "08", "Day": "10"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.5306/wjco.v12.i7.522"], "Journal": {"ISSN": "2218-4333", "JournalIssue": {"Volume": "12", "Issue": "7", "PubDate": {"Year": "2021", "Month": "Jul", "Day": "24"}}, "Title": "World journal of clinical oncology", "ISOAbbreviation": "World J Clin Oncol"}, "ArticleTitle": "Therapeutic potential of thymoquinone in combination therapy against cancer and cancer stem cells.", "Pagination": {"StartPage": "522", "EndPage": "543", "MedlinePgn": "522-543"}, "Abstract": {"AbstractText": ["The long-term success of standard anticancer monotherapeutic strategies has been hampered by intolerable side effects, resistance to treatment and cancer relapse. These monotherapeutic strategies shrink the tumor bulk but do not effectively eliminate the population of self-renewing cancer stem cells (CSCs) that are normally present within the tumor. These surviving CSCs develop mechanisms of resistance to treatment and refuel the tumor, thus causing cancer relapse. To ensure durable tumor control, research has moved away from adopting the monotreatment paradigm towards developing and using combination therapy. Combining different therapeutic modalities has demonstrated significant therapeutic outcomes by strengthening the anti-tumor potential of monotreatment against cancer and cancer stem cells, mitigating their toxic adverse effects, and ultimately overcoming resistance. Recently, there has been growing interest in combining natural products from different sources or with clinically used chemotherapeutics to further improve treatment efficacy and tolerability. Thymoquinone (TQ), the main bioactive constituent of <i>Nigella sativa,</i> has gained great attention in combination therapy research after demonstrating its low toxicity to normal cells and remarkable anticancer efficacy in extensive preclinical studies in addition to its ability to target chemoresistant CSCs. Here, we provide an overview of the therapeutic responses resulting from combining TQ with conventional therapeutic agents such as alkylating agents, antimetabolites and antimicrotubules as well as with topoisomerase inhibitors and non-coding RNA. We also review data on anticancer effects of TQ when combined with ionizing radiation and several natural products such as vitamin D3, melatonin and other compounds derived from Chinese medicinal plants. The focus of this review is on two outcomes of TQ combination therapy, namely eradicating CSCs and treating various types of cancers. In conclusion, the ability of TQ to potentiate the anticancer activity of many chemotherapeutic agents and sensitize cancer cells to radiotherapy makes it a promising molecule that could be used in combination therapy to overcome resistance to standard chemotherapeutic agents and reduce their associated toxicities."], "CopyrightInformation": "\u00a9The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, American University of Beirut, Beirut 1107 2020, Lebanon."}], "LastName": "Fatfat", "ForeName": "Zaynab", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, American University of Beirut, Beirut 1107 2020, Lebanon."}], "LastName": "Fatfat", "ForeName": "Maamoun", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, American University of Beirut, Beirut 1107 2020, Lebanon."}], "LastName": "Gali-Muhtasib", "ForeName": "Hala", "Initials": "H"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "World J Clin Oncol", "NlmUniqueID": "101549149", "ISSNLinking": "2218-4333"}, "CoiStatement": "Conflict-of-interest statement: The authors declare that they have no conflicts of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u2013249.", "ArticleIdList": ["33538338"]}, {"Citation": "Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F, Gong Z, Guo C, Li X, Deng H, Cao K, Zhou M, Xiang B, Li Y, Li G, Xiong W, Zeng Z. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 2018;37:87.", "ArticleIdList": ["PMC5914062", "29688867"]}, {"Citation": "Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AH, Mohammed OY, Elhassan GO, Harguindey S, Reshkin SJ, Ibrahim ME, Rauch C. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15:71.", "ArticleIdList": ["PMC4502609", "26180516"]}, {"Citation": "Haque MM, Desai KV. Pathways to Endocrine Therapy Resistance in Breast Cancer. Front Endocrinol (Lausanne) 2019;10:573.", "ArticleIdList": ["PMC6712962", "31496995"]}, {"Citation": "Sabnis AJ, Bivona TG. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019;25:185\u2013197.", "ArticleIdList": ["PMC6401263", "30686761"]}, {"Citation": "Mao JJ, Chung A, Benton A, Hill S, Ungar L, Leonard CE, Hennessy S, Holmes JH. Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf. 2013;22:256\u2013262.", "ArticleIdList": ["PMC4380018", "23322591"]}, {"Citation": "Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81\u201394.", "ArticleIdList": ["29115304"]}, {"Citation": "Park SY, G\u00f6nen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010;120:636\u2013644.", "ArticleIdList": ["PMC2810089", "20101094"]}, {"Citation": "Assenov Y, Brocks D, Gerh\u00e4user C. Intratumor heterogeneity in epigenetic patterns. Semin Cancer Biol. 2018;51:12\u201321.", "ArticleIdList": ["29366906"]}, {"Citation": "Jolly MK, Celi\u00e0-Terrassa T. Dynamics of Phenotypic Heterogeneity Associated with EMT and Stemness during Cancer Progression. J Clin Med. 2019;8", "ArticleIdList": ["PMC6832750", "31557977"]}, {"Citation": "Pribluda A, de la Cruz CC, Jackson EL. Intratumoral Heterogeneity: From Diversity Comes Resistance. Clin Cancer Res. 2015;21:2916\u20132923.", "ArticleIdList": ["25838394"]}, {"Citation": "Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T. Drug Resistance Driven by Cancer Stem Cells and Their Niche. Int J Mol Sci. 2017;18", "ArticleIdList": ["PMC5751177", "29194401"]}, {"Citation": "Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8:38022\u201338043.", "ArticleIdList": ["PMC5514969", "28410237"]}, {"Citation": "Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70:461\u2013477.", "ArticleIdList": ["17309302"]}, {"Citation": "Taylor WF, Jabbarzadeh E. The use of natural products to target cancer stem cells. Am J Cancer Res. 2017;7:1588\u20131605.", "ArticleIdList": ["PMC5523038", "28744407"]}, {"Citation": "Sauter ER. Cancer prevention and treatment using combination therapy with natural compounds. Expert Rev Clin Pharmacol. 2020;13:265\u2013285.", "ArticleIdList": ["32154753"]}, {"Citation": "Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod. 2020;83:770\u2013803.", "ArticleIdList": ["32162523"]}, {"Citation": "Majdalawieh AF, Fayyad MW, Nasrallah GK. Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa. Crit Rev Food Sci Nutr. 2017;57:3911\u20133928.", "ArticleIdList": ["28140613"]}, {"Citation": "Park EJ, Chauhan AK, Min KJ, Park DC, Kwon TK. Thymoquinone induces apoptosis through downregulation of c-FLIP and Bcl-2 in renal carcinoma Caki cells. Oncol Rep. 2016;36:2261\u20132267.", "ArticleIdList": ["27573448"]}, {"Citation": "Gurung RL, Lim SN, Khaw AK, Soon JF, Shenoy K, Mohamed Ali S, Jayapal M, Sethu S, Baskar R, Hande MP. Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS One. 2010;5:e12124.", "ArticleIdList": ["PMC2920825", "20711342"]}, {"Citation": "El-Najjar N, Chatila M, Moukadem H, Vuorela H, Ocker M, Gandesiri M, Schneider-Stock R, Gali-Muhtasib H. Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis. 2010;15:183\u2013195.", "ArticleIdList": ["19882352"]}, {"Citation": "Mahmoud YK, Abdelrazek HMA. Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy. Biomed Pharmacother. 2019;115:108783.", "ArticleIdList": ["31060003"]}, {"Citation": "Schneider-Stock R, Fakhoury IH, Zaki AM, El-Baba CO, Gali-Muhtasib HU. Thymoquinone: fifty years of success in the battle against cancer models. Drug Discov Today. 2014;19:18\u201330.", "ArticleIdList": ["24001594"]}, {"Citation": "Ballout F, Monzer A, Fatfat M, Ouweini HE, Jaffa MA, Abdel-Samad R, Darwiche N, Abou-Kheir W, Gali-Muhtasib H. Thymoquinone induces apoptosis and DNA damage in 5-Fluorouracil-resistant colorectal cancer stem/progenitor cells. Oncotarget. 2020;11:2959\u20132972.", "ArticleIdList": ["PMC7415406", "32821342"]}, {"Citation": "Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6:638\u2013647.", "ArticleIdList": ["19786984"]}, {"Citation": "Falzone L, Salomone S, Libra M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Front Pharmacol. 2018;9:1300.", "ArticleIdList": ["PMC6243123", "30483135"]}, {"Citation": "Khan A, Aldebasi YH, Alsuhaibani SA, Khan MA. Thymoquinone Augments Cyclophosphamide-Mediated Inhibition of Cell Proliferation in Breast Cancer Cells. Asian Pac J Cancer Prev. 2019;20:1153\u20131160.", "ArticleIdList": ["PMC6948875", "31030489"]}, {"Citation": "Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis. 2007;28:1379\u20131386.", "ArticleIdList": ["17341655"]}, {"Citation": "Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2001;2:552\u2013560.", "ArticleIdList": ["11905710"]}, {"Citation": "Dehdashti AR, Hegi ME, Regli L, Pica A, Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus. 2006;20:E6.", "ArticleIdList": ["16709037"]}, {"Citation": "Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3:198\u2013210.", "ArticleIdList": ["PMC6150109", "30258889"]}, {"Citation": "Khazaei M, Pazhouhi M. Temozolomide-Mediated Apoptotic Death Is Improved by Thymoquinone in U87MG Cell Line. Cancer Invest. 2017;35:225\u2013236.", "ArticleIdList": ["28355088"]}, {"Citation": "Pazhouhi M, Sariri R, Khazaei MR, Moradi MT, Khazaei M. Synergistic effect of temozolomide and thymoquinone on human glioblastoma multiforme cell line (U87MG) J Cancer Res Ther. 2018;14:1023\u20131028.", "ArticleIdList": ["30197342"]}, {"Citation": "Winer A, Adams S, Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther. 2018;17:1147\u20131155.", "ArticleIdList": ["PMC5984693", "29735645"]}, {"Citation": "Pazhouhi M, Sariri R, Rabzia A, Khazaei M. Thymoquinone synergistically potentiates temozolomide cytotoxicity through the inhibition of autophagy in U87MG cell line. Iran J Basic Med Sci. 2016;19:890\u2013898.", "ArticleIdList": ["PMC5048126", "27746872"]}, {"Citation": "Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265\u20137279.", "ArticleIdList": ["14576837"]}, {"Citation": "van den Berg JH, Beijnen JH, Balm AJ, Schellens JH. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev. 2006;32:390\u2013397.", "ArticleIdList": ["16781082"]}, {"Citation": "Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V, Arsenijevic N. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci. 2019;26:25.", "ArticleIdList": ["PMC6417243", "30866950"]}, {"Citation": "Wilson AJ, Saskowski J, Barham W, Yull F, Khabele D. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer. J Ovarian Res. 2015;8:46.", "ArticleIdList": ["PMC4517540", "26215403"]}, {"Citation": "Hu X, Ma J, Vikash V, Li J, Wu D, Liu Y, Zhang J, Dong W. Thymoquinone Augments Cisplatin-Induced Apoptosis on Esophageal Carcinoma Through Mitigating the Activation of JAK2/STAT3 Pathway. Dig Dis Sci. 2018;63:126\u2013134.", "ArticleIdList": ["29197940"]}, {"Citation": "Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736\u2013746.", "ArticleIdList": ["25342631"]}, {"Citation": "Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. J Exp Clin Cancer Res. 2010;29:87.", "ArticleIdList": ["PMC2909169", "20594324"]}, {"Citation": "Alaufi OM, Noorwali A, Zahran F, Al-Abd AM, Al-Attas S. Cytotoxicity of thymoquinone alone or in combination with cisplatin (CDDP) against oral squamous cell carcinoma in vitro. Sci Rep. 2017;7:13131.", "ArticleIdList": ["PMC5640598", "29030590"]}, {"Citation": "Ma J, Hu X, Li J, Wu D, Lan Q, Wang Q, Tian S, Dong W. Enhancing conventional chemotherapy drug cisplatin-induced anti-tumor effects on human gastric cancer cells both in vitro and in vivo by Thymoquinone targeting PTEN gene. Oncotarget. 2017;8:85926\u201385939.", "ArticleIdList": ["PMC5689657", "29156767"]}, {"Citation": "Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014;11:282\u2013298.", "ArticleIdList": ["24732946"]}, {"Citation": "Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, Herrmann J, Lerman A, Grothey A. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140.", "ArticleIdList": ["PMC6024329", "29977352"]}, {"Citation": "Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551\u20131569.", "ArticleIdList": ["PMC6244944", "18794772"]}, {"Citation": "Lei X, Lv X, Liu M, Yang Z, Ji M, Guo X, Dong W. Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun. 2012;417:864\u2013868.", "ArticleIdList": ["22206670"]}, {"Citation": "Kensara OA, El-Shemi AG, Mohamed AM, Refaat B, Idris S, Ahmad J. Thymoquinone subdues tumor growth and potentiates the chemopreventive effect of 5-fluorouracil on the early stages of colorectal carcinogenesis in rats. Drug Des Devel Ther. 2016;10:2239\u20132253.", "ArticleIdList": ["PMC4946859", "27468227"]}, {"Citation": "Ndreshkjana B, \u00c7apci A, Klein V, Chanvorachote P, Muenzner JK, Huebner K, Steinmann S, Erlenbach-Wuensch K, Geppert CI, Agaimy A, Ballout F, El-Baba C, Gali-Muhtasib H, Roehe AV, Hartmann A, Tsogoeva SB, Schneider-Stock R. Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells. Cell Death Dis. 2019;10:379.", "ArticleIdList": ["PMC6522523", "31097715"]}, {"Citation": "Williams S, Tucci MA, Benghuzzi HA. The effect of combination treatments of epigallocatechin-3-gallate, thymoquinone, and 5-Fluorouracil on fadu nasopharyngeal carcinoma cells. Biomed Sci Instrum. 2014;50:361\u2013366.", "ArticleIdList": ["25405445"]}, {"Citation": "Sarman H, Bayram R, Benek SB. Anticancer drugs with chemotherapeutic interactions with thymoquinone in osteosarcoma cells. Eur Rev Med Pharmacol Sci. 2016;20:1263\u20131270.", "ArticleIdList": ["27097945"]}, {"Citation": "Moysan E, Bastiat G, Benoit JP. Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications. Mol Pharm. 2013;10:430\u2013444.", "ArticleIdList": ["22978251"]}, {"Citation": "Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncol. 2005;1:7\u201317.", "ArticleIdList": ["16555971"]}, {"Citation": "Amrutkar M, Gladhaug IP. Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel) 2017;9", "ArticleIdList": ["PMC5704175", "29144412"]}, {"Citation": "Pandita A, Kumar B, Manvati S, Vaishnavi S, Singh SK, Bamezai RN. Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression. PLoS One. 2014;9:e107154.", "ArticleIdList": ["PMC4157832", "25197966"]}, {"Citation": "Mu GG, Zhang LL, Li HY, Liao Y, Yu HG. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer. Dig Dis Sci. 2015;60:1067\u20131080.", "ArticleIdList": ["25344906"]}, {"Citation": "Bashmail HA, Alamoudi AA, Noorwali A, Hegazy GA, AJabnoor G, Choudhry H, Al-Abd AM. Thymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apoptotic and autophagic activities. Sci Rep. 2018;8:11674.", "ArticleIdList": ["PMC6076303", "30076320"]}, {"Citation": "Ojima I, Lichtenthal B, Lee S, Wang C, Wang X. Taxane anticancer agents: a patent perspective. Expert Opin Ther Pat. 2016;26:1\u201320.", "ArticleIdList": ["PMC4941984", "26651178"]}, {"Citation": "Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 2019;24:40.", "ArticleIdList": ["PMC6567594", "31223315"]}, {"Citation": "Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem. 2007;2:920\u2013942.", "ArticleIdList": ["17530726"]}, {"Citation": "Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590\u20131598.", "ArticleIdList": ["11527683"]}, {"Citation": "\u015eakalar \u00c7, \u0130zgi K, \u0130skender B, Sezen S, Aksu H, \u00c7ak\u0131r M, Kurt B, Turan A, Canatan H. The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer. Tumour Biol. 2016;37:4467\u20134477.", "ArticleIdList": ["26500095"]}, {"Citation": "Bashmail HA, Alamoudi AA, Noorwali A, Hegazy GA, Ajabnoor GM, Al-Abd AM. Thymoquinone Enhances Paclitaxel Anti-Breast Cancer Activity via Inhibiting Tumor-Associated Stem Cells Despite Apparent Mathematical Antagonism. Molecules. 2020;25", "ArticleIdList": ["PMC7024316", "31968657"]}, {"Citation": "Soni P, Kaur J, Tikoo K. Dual drug-loaded paclitaxel\u2013thymoquinone nanoparticles for effective breast cancer therapy. J Nanopart Res. 2015;17:1\u201312."}, {"Citation": "Ramaswamy B, Puhalla S. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barc) 2006;42:265\u2013279.", "ArticleIdList": ["16703123"]}, {"Citation": "Akhtartavan S, Karimi M, Karimian K, Azarpira N, Khatami M, Heli H. Evaluation of a self-nanoemulsifying docetaxel delivery system. Biomed Pharmacother. 2019;109:2427\u20132433.", "ArticleIdList": ["30551502"]}, {"Citation": "Baker J, Ajani J, Scott\u00e9 F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009;13:49\u201359.", "ArticleIdList": ["19201649"]}, {"Citation": "Dirican A, Atmaca H, Bozkurt E, Erten C, Karaca B, Uslu R. Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway. Clin Transl Oncol. 2015;17:145\u2013151.", "ArticleIdList": ["25060568"]}, {"Citation": "Singh SK, Apata T, Gordetsky JB, Singh R. Docetaxel Combined with Thymoquinone Induces Apoptosis in Prostate Cancer Cells via Inhibition of the PI3K/AKT Signaling Pathway. Cancers (Basel) 2019;11", "ArticleIdList": ["PMC6770702", "31540423"]}, {"Citation": "Alkhatib MH, Bawadud RS, Gashlan HM. Incorporation of docetaxel and thymoquinone in borage nanoemulsion potentiates their antineoplastic activity in breast cancer cells. Sci Rep. 2020;10:18124.", "ArticleIdList": ["PMC7582846", "33093596"]}, {"Citation": "Zafar S, Akhter S, Ahmad I, Hafeez Z, Alam Rizvi MM, Jain GK, Ahmad FJ. Improved chemotherapeutic efficacy against resistant human breast cancer cells with co-delivery of Docetaxel and Thymoquinone by Chitosan grafted lipid nanocapsules: Formulation optimization, in vitro and in vivo studies. Colloids Surf B Biointerfaces. 2020;186:110603.", "ArticleIdList": ["31846892"]}, {"Citation": "Zafar S, Akhter S, Garg N, Selvapandiyan A, Kumar Jain G, Ahmad FJ. Co-encapsulation of docetaxel and thymoquinone in mPEG-DSPE-vitamin E TPGS-lipid nanocapsules for breast cancer therapy: Formulation optimization and implications on cellular and in vivo toxicity. Eur J Pharm Biopharm. 2020;148:10\u201326.", "ArticleIdList": ["31923585"]}, {"Citation": "Odeh F, Naffa R, Azzam H, Mahmoud IS, Alshaer W, Al Bawab A, Ismail S. Co-encapsulation of thymoquinone with docetaxel enhances the encapsulation efficiency into PEGylated liposomes and the chemosensitivity of MCF7 breast cancer cells to docetaxel. Heliyon. 2019;5:e02919.", "ArticleIdList": ["PMC6895652", "31844767"]}, {"Citation": "Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011;5:117\u2013124.", "ArticleIdList": ["PMC3063116", "21448449"]}, {"Citation": "Mahajan M, Khurana RK, Sahajpal NS, Utreja P, Sankar R, Singh B, Jain SK. Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review. Curr Drug Metab. 2015;16:453\u2013473.", "ArticleIdList": ["26264203"]}, {"Citation": "Kommineni N, Mahira S, Domb AJ, Khan W. Cabazitaxel-Loaded Nanocarriers for Cancer Therapy with Reduced Side Effects. Pharmaceutics. 2019;11", "ArticleIdList": ["PMC6470818", "30934535"]}, {"Citation": "Kommineni N, Saka R, Bulbake U, Khan W. Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer. Chem Phys Lipids. 2019;224:104707.", "ArticleIdList": ["30521787"]}, {"Citation": "Meredith AM, Dass CR. Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol. 2016;68:729\u2013741.", "ArticleIdList": ["26989862"]}, {"Citation": "Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16:3267\u20133285.", "ArticleIdList": ["19548866"]}, {"Citation": "Al-Malky HS, Al Harthi SE, Osman AM. Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. J Oncol Pharm Pract. 2020;26:434\u2013444.", "ArticleIdList": ["31594518"]}, {"Citation": "Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007;49:330\u2013352.", "ArticleIdList": ["17329180"]}, {"Citation": "Fatfat M, Fakhoury I, Habli Z, Mismar R, Gali-Muhtasib H. Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms. Life Sci. 2019;232:116628.", "ArticleIdList": ["31278946"]}, {"Citation": "Effenberger-Neidnicht K, Schobert R. Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin. Cancer Chemother Pharmacol. 2011;67:867\u2013874.", "ArticleIdList": ["20582416"]}, {"Citation": "Woo CC, Hsu A, Kumar AP, Sethi G, Tan KH. Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p38 MAPK and ROS. PLoS One. 2013;8:e75356.", "ArticleIdList": ["PMC3788809", "24098377"]}, {"Citation": "Jehan S, Zhong C, Li G, Zulqarnain Bakhtiar S, Li D, Sui G. Thymoquinone Selectively Induces Hepatocellular Carcinoma Cell Apoptosis in Synergism With Clinical Therapeutics and Dependence of p53 Status. Front Pharmacol. 2020;11:555283.", "ArticleIdList": ["PMC7522566", "33041795"]}, {"Citation": "Ibiyeye KM, Nordin N, Ajat M, Zuki ABZ. Ultrastructural Changes and Antitumor Effects of Doxorubicin/Thymoquinone-Loaded CaCO3 Nanoparticles on Breast Cancer Cell Line. Front Oncol. 2019;9:599.", "ArticleIdList": ["PMC6617642", "31334120"]}, {"Citation": "Zidan AA, El-Ashmawy NE, Khedr EG, Ebeid EM, Salem ML, Mosalam EM. Loading of doxorubicin and thymoquinone with F2 gel nanofibers improves the antitumor activity and ameliorates doxorubicin-associated nephrotoxicity. Life Sci. 2018;207:461\u2013470.", "ArticleIdList": ["29885348"]}, {"Citation": "El-Ashmawy NE, Khedr EG, Ebeid EM, Salem ML, Zidan AA, Mosalam EM. Enhanced anticancer effect and reduced toxicity of doxorubicin in combination with thymoquinone released from poly-N-acetyl glucosamine nanomatrix in mice bearing solid Ehrlish carcinoma. Eur J Pharm Sci. 2017;109:525\u2013532.", "ArticleIdList": ["28890201"]}, {"Citation": "Robati M, Holtz D, Dunton CJ. A review of topotecan in combination chemotherapy for advanced cervical cancer. Ther Clin Risk Manag. 2008;4:213\u2013218.", "ArticleIdList": ["PMC2503656", "18728710"]}, {"Citation": "Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC) Cancer Treat Rev. 2011;37:143\u2013150.", "ArticleIdList": ["20580163"]}, {"Citation": "Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2008;108:53\u201357.", "ArticleIdList": ["17904208"]}, {"Citation": "Vali AM, Toliyat T, Shafaghi B, Dadashzadeh S. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design. Drug Dev Ind Pharm. 2008;34:10\u201323.", "ArticleIdList": ["18214751"]}, {"Citation": "Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56:1\u201312.", "ArticleIdList": ["9885371"]}, {"Citation": "Khalife R, El-Hayek S, Tarras O, Hodroj MH, Rizk S. Antiproliferative and proapoptotic effects of topotecan in combination with thymoquinone on acute myelogenous leukemia. Clin Lymphoma Myeloma Leuk. 2014;14 Suppl:S46\u2013S55.", "ArticleIdList": ["25486955"]}, {"Citation": "Khalife R, Hodroj MH, Fakhoury R, Rizk S. Thymoquinone from Nigella sativa Seeds Promotes the Antitumor Activity of Noncytotoxic Doses of Topotecan in Human Colorectal Cancer Cells in Vitro. Planta Med. 2016;82:312\u2013321.", "ArticleIdList": ["26848703"]}, {"Citation": "Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8:508\u2013513.", "ArticleIdList": ["14657528"]}, {"Citation": "Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr, Kuehl WM, Staudt LM. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12:115\u2013130.", "ArticleIdList": ["PMC2730509", "17692804"]}, {"Citation": "Siveen KS, Mustafa N, Li F, Kannaiyan R, Ahn KS, Kumar AP, Chng WJ, Sethi G. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-\u03baB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget. 2014;5:634\u2013648.", "ArticleIdList": ["PMC3996662", "24504138"]}, {"Citation": "Westerdijk K, Desar IME, Steeghs N, van der Graaf WTA, van Erp NP Dutch Pharmacology and Oncology Group (DPOG) Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol. 2020;86:258\u2013273.", "ArticleIdList": ["PMC7015742", "31782166"]}, {"Citation": "Nestal de Moraes G, Souza PS, Costas FC, Vasconcelos FC, Reis FR, Maia RC. The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia. Leuk Res Treatment. 2012;2012:671702.", "ArticleIdList": ["PMC3505928", "23259070"]}, {"Citation": "Zhang Q, Li Z, Xu K, Qian Y, Chen M, Sun L, Song S, Huang X, He Z, Li F, Zhang D, Yang L, Wang Y, Xu H, Xu Z. Intracellular concentration and transporters in imatinib resistance of gastrointestinal stromal tumor. Scand J Gastroenterol. 2019;54:220\u2013226.", "ArticleIdList": ["30879345"]}, {"Citation": "Thabet NA, El-Khouly D, Sayed-Ahmed MM, Omran MM. Thymoquinone chemosensitizes human colorectal cancer cells to imatinib via uptake/efflux genes modulation. Clin Exp Pharmacol Physiol. 2021;48:911\u2013920.", "ArticleIdList": ["33783002"]}, {"Citation": "Day CM, Hickey SM, Song Y, Plush SE, Garg S. Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles. Molecules. 2020;25", "ArticleIdList": ["PMC7179425", "32151063"]}, {"Citation": "Zhang T, Feng F, Zhao W, Tian J, Yao Y, Zhou C, Dong S, Wang C, Zang C, Lv Q, Sun C. Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis. Onco Targets Ther. 2018;11:2647\u20132656.", "ArticleIdList": ["PMC5951224", "29780257"]}, {"Citation": "Ganji-Harsini S, Khazaei M, Rashidi Z, Ghanbari A. Thymoquinone Could Increase The Efficacy of Tamoxifen Induced Apoptosis in Human Breast Cancer Cells: An In Vitro Study. Cell J. 2016;18:245\u2013254.", "ArticleIdList": ["PMC4988424", "27540530"]}, {"Citation": "Rajput S, Kumar BN, Sarkar S, Das S, Azab B, Santhekadur PK, Das SK, Emdad L, Sarkar D, Fisher PB, Mandal M. Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS One. 2013;8:e61342.", "ArticleIdList": ["PMC3629226", "23613836"]}, {"Citation": "Kabel AM, Rashidy MAE, Omar MS. Ameliorative Potential of Tamoxifen/Thymoquinone Combination in Patients with Breast Cancer: A Biochemical and Immunohistochemical. J Can Sci Res. 2016;1:102."}, {"Citation": "Polascik TJ, Mouraviev V. Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag. 2008;4:261\u2013268.", "ArticleIdList": ["PMC2503661", "18728715"]}, {"Citation": "Green J, Lipton A. Anticancer properties of zoledronic acid. Cancer Invest. 2010;28:944\u2013957.", "ArticleIdList": ["20879838"]}, {"Citation": "Avil\u00e9s A, Nambo MJ, Neri N, Casta\u00f1eda C, Cleto S, Huerta-Guzm\u00e1n J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 2007;24:227\u2013230.", "ArticleIdList": ["17848748"]}, {"Citation": "Dirican A, Erten C, Atmaca H, Bozkurt E, Kucukzeybek Y, Varol U, Oktay Tarhan M, Karaca B, Uslu R. Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone- and drug-resistant prostate cancer cell lines. J BUON. 2014;19:1055\u20131061.", "ArticleIdList": ["25536616"]}, {"Citation": "Wang QQ, Jiang Y, Naranmandura H. Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases. Metallomics. 2020;12:326\u2013336.", "ArticleIdList": ["32163072"]}, {"Citation": "El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de Th\u00e9 H, Bazarbachi A. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 2000;96:2849\u20132855.", "ArticleIdList": ["11023521"]}, {"Citation": "El Hajj H, El-Sabban M, Hasegawa H, Zaatari G, Ablain J, Saab ST, Janin A, Mahfouz R, Nasr R, Kfoury Y, Nicot C, Hermine O, Hall W, de Th\u00e9 H, Bazarbachi A. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med. 2010;207:2785\u20132792.", "ArticleIdList": ["PMC3005222", "21135137"]}, {"Citation": "Hermine O, Dombret H, Poupon J, Arnulf B, Lefr\u00e8re F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC, Degos L, Varet B, de Th\u00e9 H, Bazarbachi A. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J. 2004;5:130\u2013134.", "ArticleIdList": ["15048063"]}, {"Citation": "Houssein M, Fatfat M, Habli Z, Ghazal N, Moodad S, Khalife H, Khalil M, Gali-Muhtasib H. Thymoquinone synergizes with arsenic and interferon alpha to target human T-cell leukemia/lymphoma. Life Sci. 2020;251:117639.", "ArticleIdList": ["32272181"]}, {"Citation": "Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129\u20131137.", "ArticleIdList": ["16080176"]}, {"Citation": "Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409\u2013425.", "ArticleIdList": ["PMC4896389", "26105538"]}, {"Citation": "Linam J, Yang LX. Recent developments in radiosensitization. Anticancer Res. 2015;35:2479\u20132485.", "ArticleIdList": ["25964520"]}, {"Citation": "Velho-Pereira R, Kumar A, Pandey BN, Jagtap AG, Mishra KP. Radiosensitization in human breast carcinoma cells by thymoquinone: role of cell cycle and apoptosis. Cell Biol Int. 2011;35:1025\u20131029.", "ArticleIdList": ["21557727"]}, {"Citation": "Rajput S, Kumar BN, Banik P, Parida S, Mandal M. Thymoquinone restores radiation-induced TGF-\u03b2 expression and abrogates EMT in chemoradiotherapy of breast cancer cells. J Cell Physiol. 2015;230:620\u2013629.", "ArticleIdList": ["25164250"]}, {"Citation": "Hatiboglu MA, Kocyigit A, Guler EM, Akdur K, Khan I, Nalli A, Karatas E, Tuzgen S. Thymoquinone Enhances the Effect of Gamma Knife in B16-F10 Melanoma Through Inhibition of Phosphorylated STAT3. World Neurosurg. 2019;128:e570\u2013e581.", "ArticleIdList": ["31054338"]}, {"Citation": "Goswami R, Subramanian G, Silayeva L, Newkirk I, Doctor D, Chawla K, Chattopadhyay S, Chandra D, Chilukuri N, Betapudi V. Gene Therapy Leaves a Vicious Cycle. Front Oncol. 2019;9:297.", "ArticleIdList": ["PMC6491712", "31069169"]}, {"Citation": "Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gull\u00e0 A, Tagliaferri P, Tassone P, Caraglia M. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids. 2014;3:e194.", "ArticleIdList": ["PMC4222652", "25247240"]}, {"Citation": "Imani S, Wei C, Cheng J, Khan MA, Fu S, Yang L, Tania M, Zhang X, Xiao X, Fu J. MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion. Oncotarget. 2017;8:21362\u201321379.", "ArticleIdList": ["PMC5400590", "28423483"]}, {"Citation": "Rajput S, Puvvada N, Kumar BN, Sarkar S, Konar S, Bharti R, Dey G, Mazumdar A, Pathak A, Fisher PB, Mandal M. Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes. Mol Pharm. 2015;12:4214\u20134225.", "ArticleIdList": ["26505213"]}, {"Citation": "Murillo G, Matusiak D, Benya RV, Mehta RG. Chemopreventive efficacy of 25-hydroxyvitamin D3 in colon cancer. J Steroid Biochem Mol Biol. 2007;103:763\u2013767.", "ArticleIdList": ["PMC1904391", "17257827"]}, {"Citation": "Tangpricha V, Spina C, Yao M, Chen TC, Wolfe MM, Holick MF. Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J Nutr. 2005;135:2350\u20132354.", "ArticleIdList": ["16177194"]}, {"Citation": "Vaughan-Shaw PG, Buijs LF, Blackmur JP, Theodoratou E, Zgaga L, Din FVN, Farrington SM, Dunlop MG. The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials. Br J Cancer. 2020;123:1705\u20131712.", "ArticleIdList": ["PMC7686489", "32929196"]}, {"Citation": "Mohamed AM, Refaat BA, El-Shemi AG, Kensara OA, Ahmad J, Idris S. Thymoquinone potentiates chemoprotective effect of Vitamin D3 against colon cancer: a pre-clinical finding. Am J Transl Res. 2017;9:774\u2013790.", "ArticleIdList": ["PMC5340713", "28337306"]}, {"Citation": "Luchetti F, Canonico B, Betti M, Arcangeletti M, Pilolli F, Piroddi M, Canesi L, Papa S, Galli F. Melatonin signaling and cell protection function. FASEB J. 2010;24:3603\u20133624.", "ArticleIdList": ["20534884"]}, {"Citation": "Vinther AG, Cla\u00ebsson MH. [The influence of melatonin on the immune system and cancer] Ugeskr Laeger. 2015;177:V10140568.", "ArticleIdList": ["26027592"]}, {"Citation": "Odeh LH, Talib WH, Basheti IA. Synergistic effect of thymoquinone and melatonin against breast cancer implanted in mice. J Cancer Res Ther. 2018;14:S324\u2013S330.", "ArticleIdList": ["29970684"]}, {"Citation": "Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med. 2011;17:1217\u20131220.", "ArticleIdList": ["21989013"]}, {"Citation": "Fr\u00f6hlich T, Reiter C, Saeed MEM, Hutterer C, Hahn F, Leidenberger M, Friedrich O, Kappes B, Marschall M, Efferth T, Tsogoeva SB. Synthesis of Thymoquinone-Artemisinin Hybrids: New Potent Antileukemia, Antiviral, and Antimalarial Agents. ACS Med Chem Lett. 2018;9:534\u2013539.", "ArticleIdList": ["PMC6004568", "29937978"]}, {"Citation": "Fr\u00f6hlich T, Ndreshkjana B, Muenzner JK, Reiter C, Hofmeister E, Mederer S, Fatfat M, El-Baba C, Gali-Muhtasib H, Schneider-Stock R, Tsogoeva SB. Synthesis of Novel Hybrids of Thymoquinone and Artemisinin with High Activity and Selectivity Against Colon Cancer. ChemMedChem. 2017;12:226\u2013234.", "ArticleIdList": ["27973725"]}, {"Citation": "Das S, Dey KK, Dey G, Pal I, Majumder A, MaitiChoudhury S, kundu SC, Mandal M. Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma. PLoS One. 2012;7:e46641.", "ArticleIdList": ["PMC3471895", "23077516"]}, {"Citation": "Sethi G, Shanmugam MK, Warrier S, Merarchi M, Arfuso F, Kumar AP, Bishayee A. Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review. Nutrients. 2018;10", "ArticleIdList": ["PMC5986524", "29783752"]}, {"Citation": "Bhattacharjee M, Upadhyay P, Sarker S, Basu A, Das S, Ghosh A, Ghosh S, Adhikary A. Combinatorial therapy of Thymoquinone and Emodin synergistically enhances apoptosis, attenuates cell migration and reduces stemness efficiently in breast cancer. Biochim Biophys Acta Gen Subj. 2020;1864:129695.", "ArticleIdList": ["32735937"]}, {"Citation": "Dong X, Fu J, Yin X, Cao S, Li X, Lin L Huyiligeqi. Ni J. Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics. Phytother Res. 2016;30:1207\u20131218.", "ArticleIdList": ["PMC7168079", "27188216"]}, {"Citation": "Mahendra P, Bisht S. Ferula asafoetida: Traditional uses and pharmacological activity. Pharmacogn Rev. 2012;6:141\u2013146.", "ArticleIdList": ["PMC3459456", "23055640"]}, {"Citation": "Al-Mutairi A, Rahman A, Rao MS. Low Doses of Thymoquinone and Ferulic Acid in Combination Effectively Inhibit Proliferation of Cultured MDA-MB 231 Breast Adenocarcinoma Cells. Nutr Cancer. 2021;73:282\u2013289.", "ArticleIdList": ["32223348"]}, {"Citation": "Dixon RA, Ferreira D. Genistein. Phytochemistry. 2002;60:205\u2013211.", "ArticleIdList": ["12031439"]}, {"Citation": "Ozturk SA, Alp E, Yar Saglam AS, Konac E, Menevse ES. The effects of thymoquinone and genistein treatment on telomerase activity, apoptosis, angiogenesis, and survival in thyroid cancer cell lines. J Cancer Res Ther. 2018;14:328\u2013334.", "ArticleIdList": ["29516914"]}, {"Citation": "Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene. 2001;20:3786\u20133797.", "ArticleIdList": ["11439342"]}, {"Citation": "Dera AA, Rajagopalan P, Al Fayi M, Ahmed I, Chandramoorthy HC. Indirubin-3-monoxime and thymoquinone exhibit synergistic efficacy as therapeutic combination in in-vitro and in-vivo models of Lung cancer. Arch Pharm Res. 2020;43:655\u2013665.", "ArticleIdList": ["32588331"]}, {"Citation": "Meghwal M, Goswami TK. Piper nigrum and piperine: an update. Phytother Res. 2013;27:1121\u20131130.", "ArticleIdList": ["23625885"]}, {"Citation": "Talib WH. Regressions of Breast Carcinoma Syngraft Following Treatment with Piperine in Combination with Thymoquinone. Sci Pharm. 2017;85", "ArticleIdList": ["PMC5620515", "28671634"]}, {"Citation": "Thombare N, Jha U, Mishra S, Siddiqui MZ. Guar gum as a promising starting material for diverse applications: A review. Int J Biol Macromol. 2016;88:361\u2013372.", "ArticleIdList": ["27044346"]}, {"Citation": "Das S, Bera D, Pal K, Mondal D, Karmakar P, Das S, et al. Guar gum micro-vehicle mediated delivery strategy and synergistic activity of thymoquinone and piperine: An in vitro study on bacterial and hepatocellular carcinoma cells. J Drug Deliv Sci Technol. 2020;60:101994."}, {"Citation": "Perrone D, Fuggetta MP, Ardito F, Cottarelli A, De Filippis A, Ravagnan G, De Maria S, Lo Muzio L. Resveratrol (3,5,4'-trihydroxystilbene) and its properties in oral diseases. Exp Ther Med. 2017;14:3\u20139.", "ArticleIdList": ["PMC5488484", "28672886"]}, {"Citation": "Ismail N, Abdel\u2013Mottaleb Y, Eissa Ahmed AA, El-Maraghy NN. Novel combination of thymoquinone and resveratrol enhances anticancer effect on hepatocellular carcinoma cell line. Futur J Pharm Sci. 2018;4:41\u201346."}, {"Citation": "Alobaedi OH, Talib WH, Basheti IA. Antitumor effect of thymoquinone combined with resveratrol on mice transplanted with breast cancer. Asian Pac J Trop Med. 2017;10:400\u2013408.", "ArticleIdList": ["28552110"]}, {"Citation": "Kieliszek M. Selenium\u207bFascinating Microelement, Properties and Sources in Food. Molecules. 2019;24", "ArticleIdList": ["PMC6480557", "30987088"]}, {"Citation": "Barron J, Benghuzzi H, Tucci M. Effects of thymoquinone and selenium on the proliferation of mg 63 cells in tissue culture. Biomed Sci Instrum. 2008;44:434\u2013440.", "ArticleIdList": ["19141954"]}, {"Citation": "Ibiyeye KM, Zuki ABZ. Cockle Shell-Derived Aragonite CaCO3 Nanoparticles for Co-Delivery of Doxorubicin and Thymoquinone Eliminates Cancer Stem Cells. Int J Mol Sci. 2020;21", "ArticleIdList": ["PMC7084823", "32164352"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "2", "Day": "27"}, {"Year": "2021", "Month": "4", "Day": "11"}, {"Year": "2021", "Month": "6", "Day": "18"}, {"Year": "2021", "Month": "8", "Day": "9", "Hour": "6", "Minute": "40"}, {"Year": "2021", "Month": "8", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "8", "Day": "10", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "7", "Day": "24"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34367926", "PMC8317652", "10.5306/wjco.v12.i7.522"]}}], "PubmedBookArticle": []}